We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Using Stem Cells to Kill Cancer

By Biotechdaily staff writers
Posted on 19 Oct 2005
In a development that may lead to future treatments for various types of cancer, researchers have coaxed human embryonic stem cells to create cancer-killing cells in the laboratory.

Investigators at the University of Minnesota (Minneapolis/St.Paul, MN, USA) used human embryonic stem cells to generate "natural killer” cells, which are normally found in the bloodstream and help to defend the body against infection. More...
The results also provided the researchers with a model of how the immune system develops.

"This is the first published research to show the ability to make cells from human embryonic stem cells that are able to treat and fight cancer, especially leukemias and lymphomas,” said lead author Dan Kaufman, M.D., Ph.D., assistant professor of medicine in the Stem Cell Institute and department of medicine at the University of Minnesota.

Now the researchers will test whether these human embryonic stem cell-derived natural killer cells can target cancer cells in animals. To date, the research has used two U.S. approved embryonic stem cell lines. Dr. Kaufman noted that if the research leads to a treatment for people, new lines would have to be developed. The research was reported in the October 15, 2005, issue of Cell.

"We hear a lot about the potential of stem cells to treat conditions such as Parkinson's disease, diabetes, and Alzheimer's disease,” observed Dr. Kaufman. "This research suggests it is possible that we could use human embryonic stem cells as a source for immune cells that could better target and destroy cancer cells and potentially treat infections.”



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Repetitive Pipette
VWR® Stepper Pro
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.